The Liver Meeting 2022-Hepatotoxicity SIG Program: Gut Microbiota and Drug-Induced Liver Injury-Basic Mechanisms and Clinical Applications

Hepatotoxicity SIG Program: Gut Microbiota and Drug-Induced Liver Injury-Basic Mechanisms and Clinical Applications

Video Transcription

Video Summary

This session discussed the role of the microbiome and liver injury induced by hepatotoxins. The first speaker discussed the role of short-chain fatty acids, specifically propionic acid, in protecting against acetaminophen-induced liver injury in mice. They found that propionic acid decreased liver damage and inflammation by modulating the expression of genes involved in oxidative stress and inflammation. The second speaker focused on the role of the gut microbiome in drug-induced liver injury and the potential for microbiota-based therapies. They showed that dysbiosis, or an imbalance in the gut microbiota, can increase liver injury and identified specific bacteria and metabolites that may play a role. The third speaker discussed the role of the microbiome and bile acids in liver cancer development. They found that dysbiosis can disrupt bile acid homeostasis and increase the risk of hepatocellular carcinoma. They also identified potential therapeutic targets, including microRNAs, that could be used to treat liver cancer. Overall, the session highlighted the importance of the microbiome in liver injury and the potential for microbiota-based therapies to prevent and treat liver diseases.

Keywords

microbiome

liver injury

hepatotoxins

short-chain fatty acids

acetaminophen-induced liver injury

gut microbiome

drug-induced liver injury

dysbiosis

hepatocellular carcinoma